Sperm Production Harmed by Lymphoma Treatment
the Cancer Therapy Advisor take:
Hodgkin lymphoma and non-Hodgkin lymphoma are only found in younger patients in their reproductive years.
According to a study published in Fertility and Sterility, sperm production is harmed or halted due to treatment for these white blood cell cancers. Rebecca Sokol, MD, and researchers conducted a study on 57 patients with Hodgkin lymphoma and 18 patients with non-Hodgkin lymphoma who used a sperm bank prior to cancer treatment. Researchers wanted to study various treatments and analyze how each one affects fertility for men.
Comparing the patients’ sperm to sperm from 257 fertile, healthy men, researchers studied the patients’ sperm before cancer treatment and 3 months, 6 months, 12 months, and 24 months after cancer treatment. The patients’ treatment included combination chemotherapy with or without radiation. Results indicated that sperm density, total count, motility, and vitality all decreased for patients with lymphoma.
A total halt in sperm production or an extended time before sperm production resumed were linked to alkylating chemotherapy, which damages DNA while it attacks cancer cells. Researchers found that prior to treatment, patients with lymphoma had more damaged sperm than their healthy counterparts. Although damage levels improved between 3 to 6 months after cancer treatment, the patients’ sperm were found to be more damaged than healthy sperm.
Treatment for lymphoma may lower men's fertility, new research indicates.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC